Nephrotoxic Risk Associated With Combination Therapy of Vancomycin and Piperacillin-Tazobactam in Critically Ill Patients With Chronic Kidney Disease

被引:0
|
作者
Pipkin, Tamyah [1 ,7 ]
Pope, Stuart [2 ,8 ]
Killian, Alley [1 ]
Green, Sarah [1 ]
Albrecht, Benjamin [1 ]
Nugent, Katherine [3 ,4 ,5 ,6 ]
机构
[1] Emory Univ Hosp, Dept Pharm, Atlanta, GA USA
[2] Emory Univ Hosp Midtown, Dept Pharm, Atlanta, GA USA
[3] Emory Univ, Dept Med, Sch Med, Atlanta, GA USA
[4] Emory Univ, Dept Emergency Med, Sch Med, Atlanta, GA USA
[5] Emory Univ, Dept Anesthesiol, Sch Med, Atlanta, GA USA
[6] Emory Univ, Div Crit Care Med, Sch Med, Atlanta, GA USA
[7] Norton Womens & Childrens Hosp, Dept Pharm, 4001 Dutchmans Ln, Louisville, KY 40207 USA
[8] Emory Univ Hosp Midtown, Dept Pharm, 550 Peachtree St NE, Atlanta, GA 30308 USA
关键词
acute kidney injury; vancomycin; piperacillin-tazobactam; chronic kidney disease; nephrotoxicity; INJURY;
D O I
10.1177/08850666241234577
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The combination of vancomycin and piperacillin-tazobactam (VPT) has been associated with acute kidney injury (AKI) in hospitalized patients when compared to similar combinations. Additional studies examining this nephrotoxic risk in critically ill patients have not consistently demonstrated the aforementioned association. Furthermore, patients with baseline renal dysfunction have been excluded from almost all of these studies, creating a need to examine the risk in this patient population. Methods: This was a retrospective cohort analysis of critically ill adults with baseline chronic kidney disease (CKD) who received vancomycin plus an anti-pseudomonal beta-lactam at Emory University Hospital. The primary outcome was incidence of AKI. Secondary outcomes included stage of AKI, time to development of AKI, time to return to baseline renal function, new requirement for renal replacement therapy, intensive care unit and hospital length of stay, and in-hospital mortality. Results: A total of 109 patients were included. There was no difference observed in the primary outcome between the VPT (50%) and comparator (58%) group (P = .4), stage 2 or 3 AKI (15.9% vs 6%; P = .98), time to AKI development (1.7 vs 2 days; P = .5), time to return to baseline renal function (4 vs 3 days; P = .2), new requirement for RRT (4.5% vs 1.5%; P = .3), ICU length of stay (7.3 vs 7.4 days; P = .9), hospital length of stay (19.3 vs 20.1 days; P = .87), or in-hospital mortality (15.9% vs 10.8%; P = .4). A significant difference was observed in the duration of antibiotic exposure (3.32 vs 2.62 days; P = .045 days). Conclusion: VPT was not associated with an increased risk of AKI or adverse renal outcomes. Our findings suggest that the use of this antibiotic combination should not be avoided in this patient population. More robust prospective studies are warranted to confirm these findings.
引用
收藏
页码:860 / 865
页数:6
相关论文
共 50 条
  • [21] Are Patients Receiving the Combination of Vancomycin and Piperacillin-Tazobactam at Higher Risk for Acute Renal Injury?
    Long, Brit
    April, Michael D.
    ANNALS OF EMERGENCY MEDICINE, 2018, 72 (04) : 467 - 469
  • [22] Evaluating and Mitigating Risk of Acute Kidney Injury with the Combination of Vancomycin and Piperacillin-Tazobactam in Children
    Tillman, Emma M.
    Goldman, Jennifer L.
    PEDIATRIC DRUGS, 2021, 23 (04) : 373 - 380
  • [23] Increased Risk of Acute Kidney Injury in Critically Ill Children Treated With Vancomycin and Piperacillin/Tazobactam*
    Holsen, Maya R.
    Meaney, Calvin J.
    Hassinger, Amanda B.
    Fusco, Nicholas M.
    PEDIATRIC CRITICAL CARE MEDICINE, 2017, 18 (12) : E585 - E591
  • [24] Evaluating the risk of acute kidney injury and mortality associated with concomitant use of vancomycin with piperacillin/tazobactam or meropenem in critically ill and non-critically ill patients: a systematic review and meta-analysis
    Alshehri, Abdulmajeed M.
    Al Yami, Majed S.
    Aldairem, Atheer
    Alfehaid, Lama
    Almutairi, Abdulaali R.
    Almohammed, Omar A.
    Badawoud, Amal Mohammad
    BMC INFECTIOUS DISEASES, 2025, 25 (01)
  • [25] Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin
    Rutter, W. Cliff
    Hall, Ronald G., II
    Burgess, David S.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (16) : 1211 - 1217
  • [26] Acute Kidney Injury in Non-Intensive Care and Intensive Care Patients Treated with Vancomycin and Piperacillin-Tazobactam
    Inage, Shunsuke
    Nakamura, Shotaro
    Isoe, Yuto
    Okamoto, Saori
    Uetake, Sho
    Murakami, Misato
    Yamaguchi, Ayaka
    Morishima, Masayo
    Nei, Takahito
    Ise, Yuya
    Katayama, Shiro
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2020, 87 (02) : 66 - 72
  • [27] Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study
    Miano, Todd A.
    Hennessy, Sean
    Yang, Wei
    Dunn, Thomas G.
    Weisman, Ariel R.
    Oniyide, Oluwatosin
    Agyekum, Roseline S.
    Turner, Alexandra P.
    Ittner, Caroline A. G.
    Anderson, Brian J.
    Wilson, F. Perry
    Townsend, Raymond
    Reilly, John P.
    Giannini, Heather M.
    Cosgriff, Christopher, V
    Jones, Tiffanie K.
    Meyer, Nuala J.
    Shashaty, Michael G. S.
    INTENSIVE CARE MEDICINE, 2022, 48 (09) : 1144 - 1155
  • [28] Potential nephrotoxicity of the combination therapy of vancomycin and piperacillin-tazobactam: Recommendations of the ABS working group of the DGPI with the participation of GPN experts
    Martin, Luise
    Pecar, Alenka
    Baltaci, Yeliz
    Simon, Arne
    Kohl, Stefan
    Muller, Dominik
    Forster, Johannes
    KLINISCHE PADIATRIE, 2024, 236 (05): : 280 - 288
  • [29] Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion
    Mousavi, Mariam
    Zapolskaya, Tanya
    Scipione, Marco R.
    Louie, Eddie
    Papadopoulos, John
    Dubrovskaya, Yanina
    PHARMACOTHERAPY, 2017, 37 (03): : 379 - 385
  • [30] Risk of acute kidney injury in patients receiving vancomycin and concomitant piperacillin-tazobactam or carbapenem: a multicenter, retrospective cohort study
    Wu, Dong
    Wang, Xiaowu
    Li, Guangli
    Chai, Xiuli
    Guo, Shaobo
    Zhou, Lulu
    Wang, Xiaojuan
    EXPERT OPINION ON DRUG SAFETY, 2024, : 499 - 506